Patents by Inventor Kinnari PATEL

Kinnari PATEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS
    Publication number: 20210290685
    Abstract: The present invention relates generally to methods for genetic modification of hematopoietic cells. In particular, the invention relates to use of Prostaglandin E2 (PGE2), poloxamer, and protamine sulfate to enhance transduction by a recombinant retroviral vector. The compositions and methods of the present disclosure are particularly suitable for gene therapy applications, including the treatment of monogenic genetic diseases and disorders.
    Type: Application
    Filed: July 30, 2019
    Publication date: September 23, 2021
    Inventors: Brian BEARD, Gaurav D. SHAH, Juan Antonio BUEREN RONCERO, Jose Carlos SEGOVIA SANZ, Paula RIO GALDO, Susana NAVARRO ORDONEZ, Elena ALMARZA NOVOA, Oscar QUINTANA BUSTAMANTE, Cristina MESA NUNEZ, Kenneth LAW, Kinnari PATEL
  • PRODUCTION METHODS FOR VIRAL VECTORS
    Publication number: 20210198695
    Abstract: The present disclosure provides methods for manufacturing a recombinant lentiviral vectors in an adherent bioreactor, for example, by calcium-phosphate transfection of cells grown in adherent mode on low-compaction macrocarriers in an iCELLis® bioreactor system.
    Type: Application
    Filed: August 16, 2019
    Publication date: July 1, 2021
    Inventors: David RICKS, Brian BEARD, Kenneth LAW, Raj PRABHAKAR, Kinnari PATEL
  • COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT
    Publication number: 20210154237
    Abstract: The present invention provides systems and methods for manufacturing and using gene corrected stem cells for gene therapy. In particular, herein provided are methods for treating Fanconi anemia in which a subject's stem cells are selected by a combination of high stringency CD34+ selection and low stringency CD34+ selection, genetically modified using a gene therapy vector encoding a FANC protein or a gene editing system, and administered to the subject.
    Type: Application
    Filed: April 11, 2019
    Publication date: May 27, 2021
    Inventors: Brian BEARD, Julian Sevilla NAVARRO, Gaurav SHAH, Kinnari PATEL, Raj PRABHAKAR